Heal even the toughest DFUs 
with Dermagraft®.

With living fibroblasts to help build granulation tissue and a robust bioabsorbable scaffold, Dermagraft is uniquely bioengineered for DFUs, even in weight-bearing patients.1-7

THE CHALLENGE OF HEALING STALLED DFUs IS REAL—
YET FASTER HEALING IS CRITICAL

Many factors make DFUs challenging to heal. When deciding if your treatment is tough enough for DFUs, you may want to consider these important factors:

Dysfunctional 
wound 
environment

Patient 
comorbidities

Patient 
noncompliance

In stalled DFUs, abnormalities with the patient's cells, signaling molecules, and ECM are common.8-14

Comorbid conditions may affect a patient's ability to heal.15,16

In DFUs, adherence to self-care practices is typically low.17

ECM=extracellular matrix.
DFUs put patients at risk for serious complications, including amputation.

Every 5 minutes

a lower limb amputation occurs among patients with diabetes18,*

*Based on 2014 US CDC Data.
Learn more about DFU challenges and why faster healing is critical

DERMAGRAFT 
UNIQUELY DESIGNED FOR TOUGH-TO-TREAT DFUs

With living fibroblasts to help build granulation tissue and a robust bioabsorbable scaffold, Dermagraft is uniquely bioengineered for DFUs, even in weight-bearing patients.1-7

  • Dermagraft contains healthy living fibroblasts that proliferate and produce growth factors, collagen, and ECM proteins to help build granulation tissue1-3,6
  • DFUs need healthy fibroblasts to help build granulation tissue and accelerate the healing process3,4
  • Dermagraft's bioabsorbable scaffold is robust, giving the product its structure and mechanical properties19,20
Why choose Dermagraft? ECM=extracellular matrix.

RELIABLE AND EXTENSIVE EVIDENCE 
HEALS MORE DFUs FASTER 
HELPS AVOID DFU COMPLICATIONS

64%

Relative increase in %
of patients achieving
complete DFU closure7

Randomized controlled trial data for FDA approval Real-world evidence Economic outcomes data

PROVEN RESULTS BRING
UNSURPASSED ACCESS
FOR PATIENTS WITH DFUs21

100% of Medicare contractors cover Dermagraft treatment for DFUs

100% of commercial insurance medical policies cover Dermagraft treatment for DFUs

See more about Dermagraft's
unsurpassed insurance coverage

Organogenesis' Circle of Care provides the highest-quality customer service and reimbursement support. Available resources include:

  • Benefits verification
  • Ordering and shipping information
  • Coding details
View support services

Want to keep up-to-date on Dermagraft?

Sign up now

Please refer to the Dermagraft Directions for Use for complete prescribing information.

REFERENCES:

  1. Dermagraft Directions for Use. Organogenesis Inc; 2015.
  2. Data on File-016 and -017. Organogenesis Inc.
  3. Bainbridge P. J Wound Care. 2013; 22(8):407-412.
  4. Falanga V. Lancet. 2005;366:1736-1743.
  5. Broughton G, et al. Plast Reconstr Surg. 2006;117(Suppl):12S-34S.
  6. Roberts C, et al. Can J Plast Surg. 2002;10(Suppl A):6A-13A.
  7. Marston WA, et al. Diabetes Care. 2003;26(6):1701-1705.
  8. Barrientos S, et al. Wound Repair Regen. 2008;16:585-601.
  9. Cook H, et al. J Invest Dermatol. 2000;115:225-233.
  10. Kim BC, et al. J Cell Physiol. 2003;195:331-336.
  11. Van de Berg JS, et al. Surg Clin North Am. 2003;83:509-520.
  12. Mendez MV, et al. J Vasc Surg. 1998;28(26):876-883.
  13. Wall IB, et al. J Invest Dermatol. 2008;128(10):2526-2540.
  14. Hunt TK, et al. Adv Skin Wound Care. 2000;13(suppl 2):6-11.
  15. McEwen LN, et al. J Diabetes Complications. 2013;27(6):588-592.
  16. Kelly M, et al. Int J Low Extrem Wounds. 2019;18(3):301-308.
  17. Ploderer B, et al. JMIR Diabetes. 2018;3(4):e10105.
  18. Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed December 12, 2019.
  19. Conn J, et al. Am J Surg. 1974;128:19-23.
  20. Munton CGF, et al. Br J Ophthal. 1984;58:941-947.
  21. Data on file. Organogenesis Inc.